Ercole Rao
Group Leader, Large Molecules Research- Engineered Protein Therapies Sanofi
Dr. Ercole Rao holds a PhD in Biology from the University of Heidelberg. Since joining Sanofi’s Biologics group in 2001, he has led Protein Engineering efforts for over 20 years, specializing in Multispecific Antibody Technologies. As Group Head of Engineered Protein Therapeutics, he drives innovation in antibody engineering and next-generation biologics for patient care.
Seminars
With bispecifics and T-cell engagers advancing rapidly, early-stage development carries significant translational, immunogenicity, and safety risk. This workshop will explore how to design integrated preclinical packages that better predict human pharmacology, safety, and immune-related liabilities, enabling more confident progression into the clinic. Participants will learn how to align mechanism-of-action, safety, and immunogenicity assessments to build confidence in human outcomes and accelerate early clinical decision-making.
This workshop will gather experts to discuss:
- Optimise biologics for safety, efficacy and immunogenicity to confidently de-risk bispecifics and TCEs before entering clinical studies
- Identify and mitigate immune-related and safety liabilities early, strengthening predictivity and reducing clinical development risk
- Leverage mechanism-of-action insights to integrate safety and immunogenicity considerations into preclinical packages to accelerate regulatory approval and clinic readiness
